Navigation Links
Strategy developed to improve delivery of medicines to the brain
Date:9/7/2012

New research offers a possible strategy for treating central nervous system diseases, such as brain and spinal cord injury, brain cancer, epilepsy, and neurological complications of HIV. The experimental treatment method allows small therapeutic agents to safely cross the blood-brain barrier in laboratory rats by turning off P-glycoprotein, one of the main gatekeepers preventing medicinal drugs from reaching their intended targets in the brain.

The findings appeared online Sept. 4 in the Proceedings of the National Academy of Sciences, and is the result of a study from scientists at the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health.

"Many promising drugs fail because they cannot cross the blood-brain barrier sufficiently to provide a therapeutic dose to the brain," said David Miller, Ph.D., head of the Laboratory of Toxicology and Pharmacology at NIEHS, and leader of the team that performed the study. "We hope our new strategy will have a positive impact on people with brain disorders in the future."

In a two-pronged approach, the research team first determined that treating rat brain capillaries with the multiple sclerosis drug marketed as Gilenya (fingolimod) stimulated a specific biochemical signaling pathway in the blood-brain barrier that rapidly and reversibly turned off P-glycoprotein. Team members then pretreated rats with fingolimod, and administered three other drugs that P-glycoprotein usually transports away from the brain. They observed a dramatic decline in P-glycoprotein transport activity, which led to a threefold to fivefold increase in brain uptake for each of the three drugs.

Ronald Cannon, Ph.D., is a staff scientist in the Miller lab and first author on the paper. He said one of the burning questions the team wants to tackle next is to understand how the signaling system turns off P-glycoprotein. He equates the mechanism to what happens when a person flips a light switch.

"If you physically turn off a light using the button on the wall, the light will go out because the electrical current to the light bulb has been interrupted," Cannon explained. "But what happens when the signaling pathway shuts down P-glycoprotein? Does it bring in another protein to bind to the pump, take away its energy source, modify the structure of the pump, or something else?"

Cannon said the paper's findings open a new way of thinking regarding targets for drug design, a thought that is emotionally gratifying for him and many other researchers whose scientific discoveries generally don't directly translate into helping people with illnesses.

"Although much more research needs to be done, delivering therapeutics to the central nervous system is one of the final frontiers of pharmacotherapy, Cannon added."


'/>"/>

Contact: Robin Arnette
arnetter@niehs.nih.gov
919-541-5143
NIH/National Institute of Environmental Health Sciences
Source:Eurekalert

Related medicine news :

1. Scientists devise new strategy to destroy multiple myeloma
2. Strategy May Help ER Docs Spot Heart Attacks Within an Hour
3. Scientists develop new strategy to overcome drug-resistant childhood cancer
4. Cell differentiation as a novel strategy for the treatment of an aggressive type of skin cancer
5. New gene transfer strategy shows promise for limb girdle and other muscular dystrophies
6. UT Southwestern study shows treating diabetes early, intensively is best strategy
7. VisionWare and Serco Partner to Enable ‘Digital by Default’ Strategy
8. New drug strategy attacks resistant leukemia and lymphoma
9. Strategy discovered to activate genes that suppress tumors and inhibit cancer
10. Discovery suggests new combination therapy strategy for basal-like breast cancers
11. White House Drug Policy Shifts Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... January 13, 2017 , ... With ... on the challenge of providing additional organic alternatives for customers who have grown ... the brand’s new line of all-natural activated charcoal products, Moody Zook Chief Executive ...
(Date:1/13/2017)... ... 2017 , ... An inventor from Virginia Beach, Va., is always on the ... diversify my outfits, so he decided to design something that enhances the look of ... of a belt to allow for quick, easy changing of its look. This not ...
(Date:1/13/2017)... ... 2017 , ... "We wanted to create a design for orthodontic appliances that ... from Virginia Beach, Va. , They created a prototype for the patent-pending BRACE FACERS ... braces to be customized to suit personal tastes. They can be used to create ...
(Date:1/13/2017)... ... January 13, 2017 , ... On January 11th, Finnleo ... MN, with the official send-off from Orchestra Hall in Minneapolis on Saturday, January ... Orchestra’s Music Director, leading the official launch of the sauna. After leaving Minneapolis, ...
(Date:1/13/2017)... ... January 13, 2017 , ... The Joint Corp. was ... franchise ranking. Recognized by entrepreneurs and franchisors as a top competitive measurement, the ... areas including financial strength and stability, growth rate, and brand power. , “It ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... January 16, 2017 ... Product Type (Methyl, Ethyl, Hydroxyethyl, Hydroxypropyl, Carboxymethyl ... Beverages, Surface Coatings & Paints), Region - ... the market was valued at USD 4.51 ... reach USD 6.41 Billion by 2021, at ...
(Date:1/16/2017)... Bill is an internationally experienced medical device ... leadership positions with global medical device companies, including Smith & Nephew, ... launching new products and building successful businesses in the sector and ... and North America . ... Educated at the University of ...
(Date:1/16/2017)... -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is pleased to announce ... to its Board of Directors. He is the President ... LLC . He is also the Chief Investment Officer ... firm with over $1.5 billion under management. ... analysis and portfolio management. He began his career in ...
Breaking Medicine Technology: